Neurocrine expects double-digit 2027 INGREZZA volume growth despite mid- to high single-digit net pricing headwinds

Earnings Call Insights: Neurocrine Biosciences (NBIX) Q3 2026

Management View

• “In the third quarter, we generated record net product sales of more than $1.1 billion and record profitability.” (President, CEO & Director Kyle Gano)

• “This momentum positions us well to

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.